School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Jiangsu CM Clinical Innovation Center of Degenerative Bone & Joint Disease, Wuxi TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, 214071, China.
J Ethnopharmacol. 2024 Sep 15;331:118306. doi: 10.1016/j.jep.2024.118306. Epub 2024 May 7.
Invigorating blood circulation to remove blood stasis is a primary strategy in TCM for treating vascular dementia (VaD). Danggui-Shaoyao San (DSS), as a traditional prescription for neuroprotective activity, has been proved to be effective in VaD treatment. However, its precise molecular mechanisms remain incompletely understood.
The specific mechanism underlying the therapeutic effects of DSS on VaD was explored by employing network pharmacology as well as in vivo and in viro experiment validation.
We downloaded components of DSS from the BATMAN-TCM database for target prediction. The intersection between the components of DSS and targets, PPI network, as well as GO and KEGG enrichment analysis were then performed. Subsequently, the potential mechanism of DSS predicted by network pharmacology was assessed and validated through VaD rat model induced by 2VO operation and CoCl-treated PC12 cells. Briefly, the DSS extract were first quantified by HPLC. Secondly, the effect of DSS on VaD was studied using MWM test, HE staining and TUNEL assay. Finally, the molecular mechanism of DSS against VaD was validated by Western blot and RT-QPCR experiments.
Through network analysis, 137 active ingredients were obtained from DSS, and 67 potential targets associated with DSS and VaD were identified. GO and KEGG analysis indicated that the action of DSS on VaD primarily involves hypoxic terms and HIF-1 pathway. In vivo validation, cognitive impairment and neuron mortality were markedly ameliorated by DSS. Additionally, DSS significantly reduced the expression of proteins related to synaptic plasticity and neuron apoptosis including PSD-95, SYP, Caspase-3 and BCL-2. Mechanistically, we confirmed DSS positively modulated the expression of HIF-1α and its downstream proteins including EPO, p-EPOR, STAT5, EPOR, and AKT1 in the hippocampus of VaD rats as well as CoCl-induced PC12 cells. HIF-1 inhibitor YC-1 significantly diminished the protection of DSS on CoCl-induced PC12 cell damage, with decreased HIF-1α, EPO, EPOR expression.
Our results initially demonstrated DSS could exert neuroprotective effects in VaD. The pharmacological mechanism of DSS may be related to its positive regulation on HIF-1α/EPO pathway.
活血化瘀是中医治疗血管性痴呆(VaD)的主要策略。当归芍药散(DSS)作为一种具有神经保护活性的传统方剂,已被证明对 VaD 的治疗有效。然而,其确切的分子机制尚不完全清楚。
本研究采用网络药理学以及体内和体外实验验证的方法,探讨 DSS 治疗 VaD 的具体作用机制。
我们从 BATMAN-TCM 数据库下载 DSS 的成分进行靶标预测。然后进行 DSS 成分与靶标、PPI 网络以及 GO 和 KEGG 富集分析的交集。随后,通过 2VO 手术和 CoCl 处理的 PC12 细胞诱导的 VaD 大鼠模型评估和验证网络药理学预测的 DSS 的潜在机制。简要地说,首先通过 HPLC 定量 DSS 提取物。其次,通过 MWM 测试、HE 染色和 TUNEL 测定研究 DSS 对 VaD 的影响。最后,通过 Western blot 和 RT-QPCR 实验验证 DSS 治疗 VaD 的分子机制。
通过网络分析,从 DSS 中获得了 137 种活性成分,鉴定出 67 种与 DSS 和 VaD 相关的潜在靶标。GO 和 KEGG 分析表明,DSS 对 VaD 的作用主要涉及缺氧和 HIF-1 通路。体内验证结果显示,DSS 可明显改善认知障碍和神经元死亡率。此外,DSS 还显著降低了与突触可塑性和神经元凋亡相关的蛋白的表达,包括 PSD-95、SYP、Caspase-3 和 BCL-2。机制上,我们证实 DSS 可正向调节 VaD 大鼠海马和 CoCl 诱导的 PC12 细胞中 HIF-1α 及其下游蛋白的表达,包括 EPO、p-EPOR、STAT5、EPOR 和 AKT1。HIF-1 抑制剂 YC-1 显著减弱了 DSS 对 CoCl 诱导的 PC12 细胞损伤的保护作用,同时降低了 HIF-1α、EPO、EPOR 的表达。
本研究初步表明 DSS 可在 VaD 中发挥神经保护作用。DSS 的药理学机制可能与其对 HIF-1α/EPO 通路的正向调节有关。